Breaking News, Trials & Filings

Trials & Filings in Brief: Jan. 9, 2014

Acasti, AZ, BMS, Celator, DiaMedica, GSK, Intercept, Senesco, Vertex

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I DiaMedica completes MAD trial . . . read more Senesco begins dosing in new cohort . . . read more Phase II Intercept halts NASH trial after hitting primary endpoint . . . read more Vertex posts initial HCV data . . . read more Phase III Celator hits 50% enrollment in AML trial . . . read more Approvals AZ/BMS diabetes drug approved . . . read more GSK cancer combo get accelerated approval . . . read more Filings Acasti IND cleared by FDA . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters